Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
Conditions
Brief summary
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin and gemcitabine hydrochloride work better alone or with berzosertib in treating patients with urothelial cancer.
Detailed description
PRIMARY OBJECTIVE: I. To determine if the addition of berzosertib (M6620 \[VX-970\]) to cisplatin/gemcitabine hydrochloride (gemcitabine) improves progression-free survival (PFS) relative to cisplatin/gemcitabine alone. SECONDARY OBJECTIVES: I. To compare overall survival (OS) with the addition of M6620 (VX-970) to cisplatin/gemcitabine relative to cisplatin/gemcitabine alone. II. To compare tumor response rate with the addition of M6620 (VX-970) to cisplatin/gemcitabine relative to cisplatin/gemcitabine alone. III. To compare safety with the addition of M6620 (VX-970) to cisplatin/gemcitabine relative to cisplatin/gemcitabine alone. IV. To assess the role of p53 status in predicting response to M6620 (VX-970)-based therapy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive gemcitabine hydrochloride and cisplatin as in Arm A. After completion of study treatment, patients are followed up to 36 months.
Interventions
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed metastatic urothelial carcinoma; urothelial cancer derived from the bladder, ureter or upper tract is permitted * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) with conventional techniques or as \>= 10 mm (\>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam * Patients must have access to archival tumor tissue for proposed correlative studies; these may be derived from transurethral resection of bladder tumors (TURBT), cystectomy, or biopsy; if archival tissue is not available for proposed correlatives, patients may be enrolled at the discretion of the study principal investigator (PI) (SKP) * No prior cytotoxic chemotherapy for metastatic disease; prior immunotherapy is permitted * At least 12 months have elapsed since platinum-based peri-operative treatment * Karnofsky \>= 70% (Eastern Cooperative Oncology Group \[ECOG\] performance status 0-1) * Life expectancy of greater than 3 months * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within institutional upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal * Creatinine clearance \>= 50 mL/min by either measured (using the Cockcroft-Gault, Modification of Diet in Renal Disease \[MDRD\] or Chronic Kidney Disease Epidemiology \[CKD-EPI\] formula) or calculated clearance (i.e. glomerular filtration rate \[GFR\]) * The effects of M6620 (VX-970) on the developing human fetus are unknown; for this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial may have teratogenic potential, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of M6620 (VX-970) administration * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Radiotherapy within 4 weeks of protocol therapy * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX970), cisplatin, or gemcitabine * M6620 (VX-970) is primarily metabolized by CYP3A4; therefore, concomitant administration with strong inhibitors or inducers of CYP3A4 should be avoided; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; Patient Drug Information Handout and Wallet Card should be provided to patients; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620 (VX-970), breastfeeding should be discontinued if the mother is treated with M6620 (VX-970); these potential risks may also apply to other agents used in this study * Patients with \>= grade 2 neuropathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Day of randomization, until progression, or death, assessed up to 12 months | Estimated using the product-limit method of Kaplan and Meier. Event defined as progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 36 months | Estimated using the product-limit method of Kaplan and Meier. Event defined as death from any cause. |
| Confirmed Objective Response Rate | Up to 36 months | Response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Confirmed Objective Response = CR + PR. |
| Treatment Limiting Adverse Events | Assessed from the time of initial treatment until 30 days post discontinuation of treatment, up to 36 months. | Adverse events that were fatal or led to treatment discontinuation. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) Patients receive cisplatin, 60 mg/m2, on day 1; gemcitabine, 875 mg/m2, on days 1 and 8; and berzosertib, 90 mg/m2, on days 2 and 9 of a 21-day cycle.
Berzosertib: Given IV
Cisplatin: Given IV
Gemcitabine Hydrochloride: Given IV | 46 |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) Patients receive cisplatin,70 mg/m2, on day 1 and gemcitabine, 1000 mg/m2, on days 1 and 8 of a 21-day cycle
Cisplatin: Given IV
Gemcitabine Hydrochloride: Given IV | 41 |
| Total | 87 |
Baseline characteristics
| Characteristic | Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Arm B (Gemcitabine Hydrochloride, Cisplatin) | Total |
|---|---|---|---|
| Age, Continuous | 67.5 years | 65 years | 66 years |
| Prior Neoadjuvant Cisplatin No | 41 Participants | 37 Participants | 78 Participants |
| Prior Neoadjuvant Cisplatin Yes | 5 Participants | 4 Participants | 9 Participants |
| Race/Ethnicity, Customized African American | 4 Participants | 3 Participants | 7 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Hispanic | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Unknown | 1 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized White Not Hispanic | 38 Participants | 34 Participants | 72 Participants |
| Region of Enrollment United States | 46 participants | 41 participants | 87 participants |
| Sex: Female, Male Female | 8 Participants | 11 Participants | 19 Participants |
| Sex: Female, Male Male | 38 Participants | 30 Participants | 68 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 29 / 46 | 25 / 41 |
| other Total, other adverse events | 40 / 46 | 31 / 41 |
| serious Total, serious adverse events | 29 / 46 | 12 / 41 |
Outcome results
Primary
Progression-free Survival (PFS)
Estimated using the product-limit method of Kaplan and Meier. Event defined as progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Day of randomization, until progression, or death, assessed up to 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Progression-free Survival (PFS) | 8.0 Months |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Progression-free Survival (PFS) | 8.0 Months |
95% CI: [0.69, 1.98]
Secondary
Confirmed Objective Response Rate
Response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Confirmed Objective Response = CR + PR.
Time frame: Up to 36 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Confirmed Objective Response Rate | 54 percentage of participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Confirmed Objective Response Rate | 63 percentage of participants |
p-value: 0.51Fisher Exact
Secondary
Overall Survival (OS)
Estimated using the product-limit method of Kaplan and Meier. Event defined as death from any cause.
Time frame: Up to 36 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Overall Survival (OS) | 14.4 Months |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Overall Survival (OS) | 19.8 Months |
95% CI: [0.71, 2.48]
Secondary
Treatment Limiting Adverse Events
Adverse events that were fatal or led to treatment discontinuation.
Time frame: Assessed from the time of initial treatment until 30 days post discontinuation of treatment, up to 36 months.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Hypotension | 0 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Pulmonary embolism | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Cardiac arrest | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Thrombocytopenia | 2 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Vomiting | 0 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Creatinine Increased | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Neutropenia | 2 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Leukocytosis | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Multi-organ failure | 0 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Acute kidney injury | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Urinary tract infection | 1 Participants |
| Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Respiratory failure | 1 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Urinary tract infection | 0 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Vomiting | 1 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Hypotension | 1 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Multi-organ failure | 1 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Cardiac arrest | 0 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Neutropenia | 0 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Respiratory failure | 0 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Pulmonary embolism | 1 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Thrombocytopenia | 2 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Creatinine Increased | 2 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Leukocytosis | 0 Participants |
| Arm B (Gemcitabine Hydrochloride, Cisplatin) | Treatment Limiting Adverse Events | Acute kidney injury | 0 Participants |